Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels

NCT02375828 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Neonatal Diabetes Secondary to Mutation in the Potassium Channel

Interventions

DRUG: Glibenclamide

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]